Computational Systems Chemical Biology

Methods in Molecular Biology

Volumn 672, Issue , 2011, Pages 459-488

  Oprea, Tudor I ^a   May, Elebeoba E ^b   Leitão, Andrei ^a   Tropsha, Alexander ^c  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b SANDIA NATIONAL LABORATORIES   (United States)

^c University of North Carolina   (United States)

Author keywords

Biochemical network simulations; Biological networks; Cheminformatics; Drug target clinical outcome triplets; Pharmacodynamics pharmacokinetics; QSAR modeling; Systems biology

Indexed keywords

BIOLOGY; COMPUTER SIMULATION; HUMAN; METHODOLOGY; RESEARCH; REVIEW; SYSTEMS BIOLOGY;

BIOLOGY; COMPUTATIONAL BIOLOGY; COMPUTER SIMULATION; HUMANS; RESEARCH; SYSTEMS BIOLOGY;

MLCS; MLOWN;

EID: 79952118609     PISSN: 10643745     EISSN: 19406029     Source Type: Book Series    
DOI: 10.1007/978-1-60761-839-3_18     Document Type: Chapter

References (91)

1. Voit E., Neves A. R., and Santos H. (2006) The intricate side of systems biology. Proc Natl Acad Sci U S A 103, 9452–9457.
2. Kell D. B. (2006) Theodor Bucher Lecture. Metabolomics, modelling and machine learning in systems biology – towards an understanding of the languages of cells. Delivered on 3 July 2005 at the 30th FEBS Congress and the 9th IUBMB conference in Budapest. FEBS J 273, 873–894.
3. Blinov M. L., Faeder J. R., Goldstein B., and Hlavacek W. S. (2006) A network model of early events in epidermal growth factor receptor signaling that accounts for combinatorial complexity. Biosystems 83, 136–151.
4. Ochi H. and Westerfield M. (2007) Signaling networks that regulate muscle development: lessons from zebrafish. Dev Growth Differ 49. 1–11.
5. Brandman O., Ferrell J. E., Jr., Li R., and Meyer T. (2005) Interlinked fast and slow positive feedback loops drive reliable cell decisions. Science 310, 496–498.
6. Covert M. W., Knight E. M., Reed J. L., Herrgard M. J., and Palsson B. O. (2004) Integrating high-throughput and computational data elucidates bacterial networks. Nature 429, 92–96.
7. Oprea T. I., Tropsha A, Faulon J. L., and Rintoul M. D. (2007) Systems chemical biology. Nat Chem Biol 3, 447–450.
8. Mestres J., Martin-Couce L., Gregori-Puigjane E., Cases M., and Boyer S. (2006) Ligand-based approach to in silico pharmacology: nuclear receptor profiling. J Chem Inf Model 46, 2725–2736.
9. Paolini G. V., Shapland R. H., van Hoorn W. P., Mason J. S., and Hopkins A. L. (2006) Global mapping of pharmacological space. Nat Biotechnol 24, 805–815.
10. Morphy R. and Rankovic Z. (2007) Fragments, network biology and designing multiple ligands. Drug Discov Today 12, 156–160.
11. Loging W., Harland L., and Williams-Jones B. (2007) High-throughput electronic biology: mining information for drug discovery. Nat Rev Drug Discov 6, 220–230.
12. Austin C. P., Brady L. S., Insel T. R., and Collins F. S. (2004) NIH Molecular Libraries Initiative. Science 306, 1138–1139.
13. PubChem. (2009) http://pubchem.ncbi. nlm.nih.gov/.
14. Lipinski C. A., Lombardo F., Dominy B. W., and Feeney P. J. (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46, 3–26.
15. Brown F. (2005) Editorial opinion: chemoinformatics – a ten year update. Curr Opin Drug Discov Devel 8, 298–302.
16. Olsson T. and Oprea T. I. (2001) Cheminformatics: a tool for decision-makers in drug discovery. Curr Opin Drug Discov Devel 4, 308–313.
17. Willett P. (2008) A bibliometric analysis of the literature of chemoinformatics. Aslib Proc 60, 4–17.
18. Fliri A. F., Loging W. T., Thadeio P. F., and Volkmann R. A. (2005) Biological spectra analysis: linking biological activity profiles to molecular structure. Proc Natl Acad Sci U S A 102, 261–266.
19. Schreiber S. L. (2005) Small molecules: the missing link in the central dogma. Nat Chem Biol 1, 64–66.
20. Varnek A. and Tropsha A. (2008) Cheminformatics Approaches to Virtual Screening. London: RSC.
21. Danhof M., de Lange E. C., Della Pasqua O. E., Ploeger B. A., and Voskuyl R. A. (2008) Mech-anism-based pharmacokinetic-pharmacody-namic (PK-PD) modeling in translational drug research. Trends Pharmacol Sci 29, 186–191.
22. Schmidt S., Barbour A., Sahre M., Rand K. H., and Derendorf H. (2008) PK/PD: new insights for antibacterial and antiviral applications. Curr Opin Pharmacol 8, 549–556.
23. Oprea T. and Tropsha A. (2006) Target, chemical and bioactivity databases – integration is key. Drug Discov Today 3, 357–365.
24. de Jong L. A., Uges D. R., Franke J. P., and Bischoff R. (2005) Receptor-ligand binding assays: technologies and applications. J Chromatogr B Analyt Technol Biomed Life Sci 829, 1–25.
25. SciFinder: American Chemical Society, CAS online/SciFinder. (2009) http://www.cas.org/SCIFINDER/.
26. MDDR.SYMYX technologies. (2009) http://www.mdl.com/products/knowledge/drug_ data_report/index.jsp.
27. Olah M., Rad R., Ostopovici L., Bora A., Hadaruga N., Hadaruga D. et al. (2007) WOMBAT and WOMBAT-PK: bioactivity databases for lead and drug discovery. In: Schreiber S. L., Kapoor T. M., Weiss G. (Eds). Chemical Biology: From Small Molecules to Systems Biology and Drug Design. New York: Wiley-VCH, 760–786.
28. Brunton L, Lazo J, Parker K.(Eds). (2006) Goodman and Gilman’s The Pharmacological Basis of Therapeutics. 11th ed. New York: McGraw-Hill; 1984 pp.
29. Physicians’ Desk Reference (2009) 63rd ed. PDR., Montvale, NJ, Thomson Reuters, 3315 pp.
30. FDA Approved Drug Products (2009) Available from http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm
31. Vaz R. and Klabunde T. (2008) Antitargets: prediction and prevention of drug side effects. In: Methods and Principles in Medicinal Chemistry. Weinheim: Wiley-VCH.
32. Chen X., Liu M., and Gilson M. K. (2001) BindingDB: a web-accessible molecular recognition database. Comb Chem High Throughput Screen 4, 719–725.
33. Strausberg R. L. and Schreiber S. L. (2003) From knowing to controlling: a path from genomics to drugs using small molecule probes. Science 300, 294–295.
34. Kanehisa M., Goto S., Hattori M., Aoki-Kinoshita K. F., Itoh M., Kawashima S. et al. (2006) From genomics to chemical genomics: new developments in KEGG. Nucleic Acids Res 34(Database issue), D354–D357.
35. Snyder K. A., Feldman H. J., Dumontier M., Salama J. J., and Hogue C. W. (2006) Domain-based small molecule binding site annotation. BMC Bioinformatics 7, 152.
36. Garcia-Serna R., Ursu O., Oprea T., and Mestres J. (2010) iPHACE: integrative navigation in pharmacological space. Bioinformatics. 26, 985–986.
37. Okuno Y., Yang J., Taneishi K., Yabuuchi H., and Tsujimoto G. (2006) GLIDA: GPCR-ligand database for chemical genomic drug discovery. Nucleic Acids Res 34 (Database issue), D673–D677.
38. KEGG. (2009.) http://www.genome.jp/kegg/.
39. Berman H. M., Westbrook J., Feng Z., Gilli-land G., Bhat T. N., Weissig H. et al. (2000) The Protein Data Bank. Nucleic Acids Res 28, 235–242.
40. ChemSpider. (2009) ChemSpider. http://www.chemspider.com.
41. Amidon G. L., Lennernas H., Shah V. P., and Crison J. R. (1995) A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12, 413–420.
42. Wu C. Y. and Benet L. Z. (2005) Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 22, 11–23.
43. Benet L. Z., Amidon G. L., Barends D. M., Lennernas H., Polli J. E., Shah V. P. et al. (2008) The use of BDDCS in classifying the permeability of marketed drugs. Pharm Res 25, 483–488.
44. Drews J. and Ryser S. (1997) The role of innovation in drug development. Nat Biotechnol 15, 1318–1319.
45. Imming P., Sinning C., and Meyer A. (2006) Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov 5, 821–834.
46. Overington J. P., Al Lazikani B., and Hopkins A. L. (2006) How many drug targets are there? Nat Rev Drug Discov 5, 993–996.
47. Hopkins A. L. and Groom C. R. (2002) The druggable genome. Nat Rev Drug Discov 1, 727–730.
48. Wishart D. S., Knox C., Guo A. C., Shrivastava S., Hassanali M., Stothard P. et al. (2006) DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res 34 (Database issue), D668–D672.
49. Campillos M., Kuhn M., Gavin A. C., Jensen L. J., and Bork P. (2008) Drug target identification using side-effect similarity. Science 321, 263–266.
50. Brooijmans N. and Kuntz I. D. (2003) Molecular recognition and docking algorithms. Annu Rev Biophys Biomol Struct 32, 335–373.
51. Kitchen D. B., Decornez H., Furr J. R., and Bajorath J. (2004) Docking and scoring in virtual screening for drug discovery: methods and applications. Nat Rev Drug Discov 3, 935–949.
52. Kuntz I. D., Blaney J. M., Oatley S. J, Langridge R., and Ferrin T. E. (1982) A geometric approach to macromolecule-ligand interactions. J Mol Biol 161, 269–288.
53. Wlodawer A. and Vondrasek J. (1998) Inhibitors of HIV-1 protease: a major success of structure-assisted drug design. Annu Rev Biophys Biomol Struct 27, 249–284.
54. Wong C. F. and McCammon J. A. (2003) Protein flexibility and computer sided drug design. Annual Rev Pharmacol Toxicol 43, 31–45.
55. Taylor R. D., Jewsbury P. J. and Essex J. W. (2002) A review of protein-small molecule docking methods. J Comput Aided Mol Des 16, 151–166.
56. Muegge I. (2003) Selection criteria for drug-like compounds. Med Res Rev 23, 302–321.
57. Cho S. J., Zheng W., and Tropsha A. (1998) Rational combinatorial library design. 2. Rational design of targeted combinatorial peptide libraries using chemical similarity probe and the inverse QSAR approaches. J Chem Inf Comput Sci 38, 259–268.
58. Jones G., Willett P., Glen R. C., Leach A. R., and Taylor R. (1997) Development and validation of a genetic algroithm for flexible docking. J Mol Biol 267, 727–748.
59. Warren G. L., Andrews C. W., Capelli A. M., Clarke B., LaLonde J., Lambert M. H. et al. (2006) A critical assessment of docking programs and scoring functions. J Med Chem 49, 5912–5931.
60. Keiser M. J., Roth B. L., Armbruster B. N., Ernsberger P., Irwin J. J., and Shoichet B. K. (2007) Relating protein pharmacology by ligand chemistry. Nat Biotechnol 25, 197–206.
61. Keiser M. J., Setola V., Irwin J. J., Laggner C., Abbas A. I., Hufeisen S. J. et al. (2009) Predicting new molecular targets for known drugs. Nature 462, 175–181.
62. Tropsha A. (2005) Application of predictive QSAR models to database mining. In: Oprea T. (Ed.). Cheminformatics in Drug Discovery. Wiley-VCH, Weinheim, 437–455.
63. Tropsha A. and Golbraikh A. (2007) Predictive QSAR modeling workflow, model applicability domains, and virtual screening. Curr Pharm Des 13, 3494–3504.
64. Golbraikh A. and Tropsha A. (2002) Beware of q2! J Mol Graph Model 20, 269–276.
65. Tropsha A., Gramatica P., and Gombar V. K. (2003) The importance of being earnest: validation is the absolute essential for successful application and interpretation of QSPR models. Quant Struct Act Relat Comb Sci 22, 69–77.
66. Sachs, L. (1984) Applied Statistics: A Handbook of Techniques. 2nd ed, New York: Springer-Verlag.
67. Golbraikh A., Shen M., Xiao Z., Xiao Y. D., Lee K. H, and Tropsha A. (2003) Rational selection of training and test sets for the development of validated QSAR models. J Comput Aided Mol Des 17, 241–253.
68. Irwin J. J. and Shoichet B. K. (2005) ZINC – a free database of commercially available compounds for virtual screening. J Chem Inf Model 45, 177–182.
69. Medina-Franco J. L., Golbraikh A., Oloff S., Castillo R., and Tropsha A. (2005) Quantitative structure-activity relationship analysis of pyridinone HIV-1 reverse transcriptase inhibitors using the k nearest neighbor method and QSAR-based database mining. J Comput Aided Mol Des 19, 229–242.
70. Oloff S., Mailman R. B., and Tropsha A. (2005) Application of validated QSAR models of D1 dopaminergic antagonists for database mining. J Med Chem 48, 7322–7332.
71. Shen M., Beguin C., Golbraikh A., Stables J. P., Kohn H., and Tropsha A. (2004) Application of predictive QSAR models to database mining: identification and experimental validation of novel anticonvulsant compounds. J Med Chem 47, 2356–2364.
72. Zhang S., Wei L., Bastow K., Zheng W., Brossi A., Lee K. H. et al. (2007) Antitumor agents 252. Application of validated QSAR models to database mining: discovery of novel tylophorine derivatives as potential anticancer agents. J Comput Aided Mol Des 21, 97–112.
73. Tang H., Wang X. S., Huang X. P., Roth B. L., Butler K. V., Kozikowski A. P. et al. (2009) Novel inhibitors of human histone deacetylase (HDAC) identified by QSAR modeling of known inhibitors, virtual screening, and experimental validation. J Chem Inf Model 49, 461–476.
74. Hoops S., Sahle S., Gauges R., Lee C., Pahle J., Simus N. et al. (2006) COPASI – a COmplex PAthway SImulator. Bioinformatics 22, 3067–3074.
75. Loew L. M. and Schaff J. C. (2001) The virtual cell: a software environment for computational cell biology. Trends Biotechnol 19, 401–406.
76. Slepoy A., Thompson A. P., and Plimpton S. J. (2008) A constant-time kinetic Monte Carlo algorithm for simulation of large biochemical reaction networks. J Chem Phys 128, 205101.
77. Salis H., Sotiropoulos V., and Kaznessis Y. N. (2006) Multiscale Hy3S: hybrid stochastic simulation for supercomputers. BMC Bioinformatics 7, 93.
78. Tomita M., Hashimoto K., Takahashi K., Shimizu T. S., Matsuzaki Y., Miyoshi F. et al. (1999) E-CELL: software environment for whole-cell simulation. Bioinformatics 15, 72–84.
79. Yang C. R., Shapiro B. E., Mjolsness E. D., and Hatfield G. W. (2005) An enzyme mechanism language for the mathematical modeling of metabolic pathways. Bioinformatics 21, 774–780.
80. May E. E. and Schiek R. L. (2009) BioXyce: an engineering platform for the study of cellular systems. IET Syst Biol 3, 77–89.
81. Schiek R. L. and May E. E. (2006) Xyce Parallel Electronic Simulator: Biological Pathway Modeling and Simulation. Albuquerque, NM, Sandia National Laboratories, Report No. SAND2006-1993p.
82. Eldred M. S., Adams B. M., Haskell K., Bohnhoff W. J., Eddy J. P., Gay D. M. et al. (2008) DAKOTA: A Multilevel Parallel Object-Oriented Framework for Design Optimization, Parameter Estimation, Uncer- tainty Quantification, and Sensitivity Analysis. Version 4.2 Users Manual. SAND2006-6337.
83. Oishi M. and May E. E. (2007) Addressing biological circuit simulation accuracy: Reach-ability for parameter identification and initial conditions. Bethesda, MD. IEEE/NIH BISTI Life Science Systems and Application Workshop.
84. Chang A., Scheer M., Grote A., Schomburg I., and Schomburg D. (2009) BRENDA, AMENDA and FRENDA the enzyme information system: new content and tools in 2009. Nucleic Acids Res 37(Database issue), D588–D592.
85. Schomburg I., Chang A., Ebeling C., Gremse M., Heldt C., Huhn G. et al. (2004) BRENDA, the enzyme database: updates and major new developments. Nucleic Acids Res 32(Database issue), D431–D433.
86. Wayne L. G. and Sohaskey C. D. (2001) Non-replicating persistence of Mycobacterium tuberculosis. Annu Rev Microbiol 55, 139–163.
87. Wayne L. G. and Lin K. Y. (1982) Glyoxylate metabolism and adaptation of Mycobacterium tuberculosis to survival under anaerobic conditions. Infect Immun 37, 1042–1049.
88. Goodford P. J. (1985) A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. J Med Chem 28, 849–857.
89. Mdluli K. and Spigelman M. (2006) Novel targets for tuberculosis drug discovery. Curr Opin Pharmacol 6, 459–467.
90. Ariens E. J., Simonis A. M., and De Groot W. M. (1955) Affinity and intrinsic-activity in the theory of competitive-and non-competitive inhibition and an analysis of some forms of dualism in action. Arch Int Pharmacodyn Ther 100, 298–322.
91. Olah M., Oprea T. I. (2006) Bioactivity Databases. In: J. B. Taylor, D. J. Triggle (Eds.). Comprehensive Medicinal Chemistry II Vol. 3. Elsevier, Oxford, 293–313.